Saxsons Group

NM Physician's Notes · Lu-177 n.c.a.

Three numbers separate genuine n.c.a. from everything else marketed as n.c.a.

Specific activity ≥ 3,000 GBq/mg. Radionuclidic purity ≥ 99.9 %. Radiochemical purity ≥ 99 %. Each of these specs is described in the Lu-177 release certificate; each looks like a headline number; each one is doing real work in the radiopharmacy. This post unpacks why a Lu-177 supply that misses any one of them is not actually n.c.a. — and what changes in your patient's cycle when that distinction is collapsed.

The four-spec snapshot

n.c.a. vs carrier-added — what's actually in the vial

Specification n.c.a. Lu-177 (SHINE) Carrier-added Lu-177 Why it matters
Specific activity ≥ 3,000 GBq/mg (peaks ≈ 3,700) ~500 – 1,100 GBq/mg (typical CA grade) Determines how much cold lutetium competes against ¹⁷⁷Lu for the peptide chelation site. Drives labelling yield and tumour-to-background.
Radionuclidic purity (RNP) ≥ 99.9 % ¹⁷⁷Lu ≥ 99.9 % at calibration — but with Lu-177m present at trace level The remaining 0.1 % is what counts. In CA grade it is mostly Lu-177m (T½ ≈ 160 d). In n.c.a. it is essentially absent.
Radiochemical purity (RCP) ≥ 99 % as ¹⁷⁷LuCl₃ Variable — depends on pH stability of the matrix Free Lu(III) chloride is the species that DOTATATE / PSMA-617 / FAPI can chelate. Lu(OH)₃ colloid cannot.
Lu-177m metastable Negligible (below routine detection limit) ≈ 10⁻² to 10⁻⁴ relative to ¹⁷⁷Lu Lu-177m (T½ ≈ 160 d) drives long-tail organ dose and dictates decay-store dwell time for spent vials and patient excreta.

Source: SHINE FDA Drug Master File summary; Ph. Eur. monograph 2798 (Lutetium-177 chloride); IAEA TECDOC-1955 (Lu-177 production routes).

Spec 1 — Specific activity ≥ 3,000 GBq/mg

Why higher specific activity is unambiguously better

  • A theranostic peptide (DOTATATE, PSMA-617, FAPI-46) has one chelation site per molecule. The site binds Lu(III) — it does not distinguish ¹⁷⁵Lu, ¹⁷⁶Lu or ¹⁷⁷Lu.
  • Carrier-added (CA) Lu-177 is produced by direct neutron capture on a Lu-176 target: ¹⁷⁶Lu(n,γ)¹⁷⁷Lu. The matrix that comes out of the reactor contains bulk stable Lu-175 / Lu-176 (the "carrier") plus the activated Lu-177.
  • n.c.a. Lu-177 is produced indirectly via Yb-176: ¹⁷⁶Yb(n,γ)¹⁷⁷Yb → β⁻ → ¹⁷⁷Lu. A chemical separation strips the ytterbium parent, leaving a Lu fraction in which essentially every Lu atom is ¹⁷⁷Lu.
  • The ratio is large. CA Lu-177 lands around 500 – 1,100 GBq/mg of total Lu in the matrix. n.c.a. Lu-177 (SHINE Medical) delivers ≥ 3,000 GBq/mg at calibration with batches reaching ≈ 3,700 GBq/mg. The theoretical ceiling for carrier-free Lu-177 is ~4,070 GBq/mg — n.c.a. is at ~85–90 % of that ceiling.
  • For a 7.4 GBq cycle, the carrier-added peptide mass to chelate that activity is ≈ 12 mg. The n.c.a. peptide mass is ≈ 2.5 mg. The lower peptide load means more activity reaches the tumour receptor population and less is wasted saturating normal-tissue background — directly visible as a higher tumour-to-background ratio on post-therapy SPECT/CT.

Source: Dash A et al. Production of ¹⁷⁷Lu for targeted radionuclide therapy: a review. Nucl Med Biol 2015; 42:651-665. SHINE FDA Drug Master File.

Spec 2 — Radionuclidic purity ≥ 99.9 % ¹⁷⁷Lu

The 0.1 % is what matters — and it's not the same 0.1 %

  • "Radionuclidic purity" is the fraction of activity that comes from the intended radionuclide. The Ph. Eur. monograph for Lutetium-177 chloride requires ≥ 99.9 % at calibration.
  • 99.9 % sounds nearly complete. The 0.1 % is what matters — because what is in that 0.1 % differs entirely between CA and n.c.a. grades.
  • CA Lu-177 production also activates Lu-176 along a secondary channel that produces Lu-177m — a metastable nuclear isomer of Lu-177 with a 160.4-day half-life. The standard release certificate may meet the 99.9 % threshold at calibration time, but the residual 0.1 % is overwhelmingly Lu-177m. After two weeks of decay the parent Lu-177 has halved roughly twice; the Lu-177m has barely moved. The vial that left the reactor at 99.9 % RNP no longer sits at 99.9 % when it reaches the clinic.
  • n.c.a. Lu-177 — because it routes through Yb-176 → Yb-177 → Lu-177 — has no production channel for Lu-177m. The 0.1 % impurity, if measurable, is short-lived activation products that decay alongside the parent.
  • Why this matters clinically: Lu-177m contributes disproportionately to long-tail kidney dose during multi-cycle therapy and forces a long decay-store dwell time for spent vials and patient excreta. A CA-Lu-177 vial may need a full year in the decay store before clearing AERB release thresholds; an n.c.a. vial decays in weeks.

Source: IAEA TECDOC-1955 — Production of Long-Lived Parent Radionuclides. Ph. Eur. monograph 2798. AERB Atomic Energy (Radiation Protection) Rules 2004.

Spec 3 — Radiochemical purity ≥ 99 % as ¹⁷⁷LuCl₃

Free Lu(III) is the only species the peptide can label

  • "Radiochemical purity" is the fraction of activity that exists in the intended chemical species. For the Ph. Eur. ¹⁷⁷LuCl₃ monograph, the intended species is free Lu(III) chloride in dilute HCl. The release spec is ≥ 99 %.
  • The other ≤ 1 % is mostly colloidal lutetium hydroxide — Lu(OH)₃ — which forms when the dilute HCl matrix drifts toward neutral pH during storage. Lu(OH)₃ is a polymeric colloid; DOTATATE, PSMA-617 and FAPI peptide chelators cannot complex it.
  • A 1 % colloidal fraction effectively means 1 % of the activity in the vial cannot be labelled. The peptide labelling kit reads the colloid as inert mass — radiochemical-purity drift below 99 % directly converts to a labelled-product yield gap, biodistribution shift toward liver / spleen (RES uptake of free Lu species), and out-of-spec release on the radiopharmacy QC.
  • The 0.04 M HCl matrix in which n.c.a. Lu-177 is supplied is the recommended pH range — acidic enough to keep Lu(III) in chloride form. Maintaining the matrix from production to labelling is part of why cold-chain delivery and tight calibration windows matter.

Source: Ph. Eur. monograph 2798 (Lutetium-177 chloride solution); EANM procedural guidelines for PRRT.

The definition

Why < 99.9 % RNP with detectable Lu-177m is not actually n.c.a.

  • "n.c.a." is a production-route definition, not just a purity number. It is defined by what is in the matrix, not by what is on the release certificate.
  • CA Lu-177 cannot be n.c.a. by definition — the Lu-176 target itself contributes bulk stable Lu, and the same neutron flux that makes Lu-177 also makes Lu-177m. A CA-process product can publish 99.9 % RNP at calibration, but the long-lived Lu-177m component disqualifies it from the n.c.a. classification regardless of the headline number.
  • A genuine n.c.a. Lu-177 supply has three signatures together: production from a Yb-176 target with chemical separation, specific activity well above the CA ceiling (≥ 3,000 GBq/mg vs ~600), and Lu-177m present below routine detection.
  • If any of those three signatures is missing — particularly if Lu-177m is present at the level CA grade carries — the product is not n.c.a., regardless of how the supplier markets it. The chemistry, kidney dose tail and decay-store behaviour will be CA, not n.c.a.

Source: Dash A et al. Nucl Med Biol 2015; IAEA TECDOC-1955; SHINE FDA Drug Master File summary on the Yb-176 → Yb-177 → Lu-177 production route.

Lu-177 n.c.a.

More for this product

Sibling posts in the Lu-177 n.c.a. family.

For Nuclear-Medicine Physician

Nuclear-Medicine Physician

One Lu-177 supply, three theranostic clinics

DOTATATE for NETs, PSMA-617 for prostate, FAPI for tumour-stroma — three indications sharing one n.c.a. supply chain. What shares upstream, what doesn't share downstream, and three traps that catch first-time programmes.

Read this